Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 26, 2022 07:30 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures

BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal...
July 19, 2022 16:30 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)

- Rapid and significant increase in plasma pyrophosphate (PPi) levels observed in all three subjects in lowest dose cohort (0.2 mg/kg) – - INZ-701 was generally well-tolerated and exhibited a...
June 16, 2022 07:30 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma Announces Partnership with Rady Children’s Institute for Genomic Medicine to Advance Newborn Screening for Genetic Diseases

BOSTON, June 16, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal...
June 07, 2022 07:30 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical Officer

BOSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal...
June 01, 2022 07:30 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma to Present at the 2022 Jefferies Healthcare Conference

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal...
May 10, 2022 07:30 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business Highlights

– Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency – – Preliminary biomarker and safety data from ongoing Phase...
May 03, 2022 07:30 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma to Present at Upcoming Investor Conferences

BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization,...
April 14, 2022 08:16 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-Market

BOSTON, April 14, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal...
April 12, 2022 07:30 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency

- First patient dosed in Phase 1/2 clinical trial in ABCC6 Deficiency – - Preliminary biomarker and safety data from Phase 1/2 clinical trial in ABCC6 Deficiency expected in the second quarter of...
April 06, 2022 07:30 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma to Present at the 21st Annual Needham Virtual Healthcare Conference

BOSTON, April 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization,...